title: [New directions in biomarker research, drug development and personalized medicine].
abstract: In recent years, medicine has taken some important first steps toward a major paradigm shift that could result in a landslide for personalized therapies. Indeed, evidence-based medicine seems to yield to personalized medicine in multiple areas, including both the thinking patterns of healthcare workers and everyday medical practice. Nevertheless, although a steadily increasing number of personalized treatment modalities have recently become available for patients, so far, no breakthrough can be seen in the paradigm shift from evidence-based medicine to personalized therapy. We believe that a more efficient identification and utilisation of future and already known biomarkers, respectively, might be the key to speed up this progress. In line with this, biomarkers are becoming increasingly important tools in late stage research, drug development and in clinical practice, as well. Correct classification of biomarkers becomes especially important, as different types of biomarkers provide markedly different information to drug developers and health care professionals.
authors.affiliation: Magyar Személyre Szabott Társaság, Budapest, Hungary. gy.nemeth@richter.hu
authors.forename: György
authors.initials: G
authors.lastname: Németh
authors.forename: Ivett
authors.initials: I
authors.lastname: Jelinek
mesh_terms: D015415:Biomarkers; D014408:Biomarkers, Tumor; D002908:Chronic Disease / Q000188:drug therapy; D015195:Drug Design; D019317:Evidence-Based Medicine; D006801:Humans; D058990:Molecular Targeted Therapy / Q000639:trends; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D057089:Pathology, Molecular; D010597:Pharmacogenetics; D057285:Precision Medicine / Q000639:trends; D011237:Predictive Value of Tests; D011379:Prognosis; D011933:Reagent Kits, Diagnostic
chemical_list: D015415:Biomarkers; D014408:Biomarkers, Tumor; D011933:Reagent Kits, Diagnostic